Trevi Therapeutics (TRVI) Change in Acquisitions & Divestments (2022 - 2026)

Trevi Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $25.6 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 45.22% year-over-year to $25.6 million in Q1 2026; TTM through Mar 2026 was $84.5 million, a 16.76% increase from a year earlier, with the FY2025 full-year figure at $76.6 million, down 0.52% from the prior year.
• Change in Acquisitions & Divestments grew to $25.6 million in Q1 2026 per TRVI's latest filing, from $23.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $25.6 million in Q1 2026 and bottomed at $12.8 million in Q2 2024.
• The 5-year median for Change in Acquisitions & Divestments is $18.8 million (2023), against an average of $19.0 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 54.34% in 2024; the steepest drop was 35.19% in 2024.
• Year by year, Change in Acquisitions & Divestments stood at $17.0 million in 2022, then retreated by 18.72% to $13.8 million in 2023, then jumped by 54.34% to $21.3 million in 2024, then climbed by 11.54% to $23.8 million in 2025, then advanced by 7.42% to $25.6 million in 2026.
• Per Business Quant, the three latest TRVI Change in Acquisitions & Divestments figures stand at $25.6 million (Q1 2026), $23.8 million (Q4 2025), and $20.7 million (Q3 2025).